Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADH dehydrogenase [ubiquinone] 1 subunit C2 (NDUFC2) is a nuclear-encoded accessory subunit of mitochondrial complex I, the first and largest enzyme of the electron transport chain. NDUFC2 is essential for the assembly and activity of complex I, facilitating electron transfer from NADH to ubiquinone. Deficiency or decreased expression of NDUFC2 leads to mitochondrial dysfunction, increased oxidative stress, and impaired ATP synthesis. NDUFC2 dysfunction is implicated in the pathogenesis of several diseases including mitochondrial disorders, diabetes, cancer, and cardiovascular conditions such as stroke. Resveratrol, an antioxidant molecule, can counteract reactive oxygen species generation due to NDUFC2 deficiency, highlighting its relevance as a potential therapeutic target[1][2][3][5].
Enhancement of mitochondrial function and reduction of ROS by antioxidants (e.g., resveratrol) Potential restoration of complex I activity
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADH dehydrogenase [ubiquinone] 1 subunit C2 (NDUFC2).